California Public Employees Retirement System Has $34.33 Million Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

California Public Employees Retirement System reduced its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 21.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 179,330 shares of the biopharmaceutical company’s stock after selling 48,500 shares during the period. California Public Employees Retirement System’s holdings in Alnylam Pharmaceuticals were worth $34,326,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of ALNY. U.S. Capital Wealth Advisors LLC acquired a new position in shares of Alnylam Pharmaceuticals in the third quarter valued at $10,892,000. Harbor Capital Advisors Inc. increased its holdings in shares of Alnylam Pharmaceuticals by 6.0% in the third quarter. Harbor Capital Advisors Inc. now owns 2,887 shares of the biopharmaceutical company’s stock valued at $511,000 after purchasing an additional 163 shares during the last quarter. Commonwealth Equity Services LLC grew its stake in shares of Alnylam Pharmaceuticals by 9.1% in the third quarter. Commonwealth Equity Services LLC now owns 4,372 shares of the biopharmaceutical company’s stock valued at $774,000 after acquiring an additional 363 shares in the last quarter. Xponance Inc. grew its stake in shares of Alnylam Pharmaceuticals by 0.7% in the third quarter. Xponance Inc. now owns 14,984 shares of the biopharmaceutical company’s stock valued at $2,654,000 after acquiring an additional 109 shares in the last quarter. Finally, Raymond James & Associates grew its stake in shares of Alnylam Pharmaceuticals by 5.1% in the third quarter. Raymond James & Associates now owns 12,411 shares of the biopharmaceutical company’s stock valued at $2,198,000 after acquiring an additional 598 shares in the last quarter. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

ALNY has been the topic of several research reports. Cantor Fitzgerald restated a “neutral” rating and issued a $165.00 price target on shares of Alnylam Pharmaceuticals in a research note on Tuesday, February 20th. JPMorgan Chase & Co. upped their price target on shares of Alnylam Pharmaceuticals from $150.00 to $170.00 and gave the company a “neutral” rating in a research note on Thursday, February 1st. Wells Fargo & Company decreased their price target on shares of Alnylam Pharmaceuticals from $171.00 to $161.00 and set an “equal weight” rating on the stock in a research note on Friday, February 16th. Citigroup decreased their price target on shares of Alnylam Pharmaceuticals from $237.00 to $227.00 and set a “buy” rating on the stock in a research note on Friday, February 16th. Finally, The Goldman Sachs Group cut shares of Alnylam Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their price objective for the stock from $230.00 to $173.00 in a research report on Friday, February 16th. Eight equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat, Alnylam Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $215.88.

Alnylam Pharmaceuticals Trading Down 0.3 %

ALNY stock opened at $143.31 on Friday. The stock has a market capitalization of $18.05 billion, a P/E ratio of -40.26 and a beta of 0.39. Alnylam Pharmaceuticals, Inc. has a 12 month low of $141.98 and a 12 month high of $218.88. The firm has a 50-day moving average price of $150.29 and a 200-day moving average price of $165.97.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, February 15th. The biopharmaceutical company reported ($1.10) EPS for the quarter, topping analysts’ consensus estimates of ($1.20) by $0.10. The company had revenue of $439.72 million during the quarter, compared to the consensus estimate of $439.38 million. The firm’s revenue was up 31.2% compared to the same quarter last year. During the same period last year, the company posted ($1.68) EPS. As a group, equities analysts predict that Alnylam Pharmaceuticals, Inc. will post -4.46 EPS for the current fiscal year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.